School of Medicine, Deakin University, 75 Pigdons Road, Waurn Ponds, Victoria 3216, Australia.
Br J Cancer. 2013 Feb 19;108(3):486-92. doi: 10.1038/bjc.2012.586. Epub 2013 Jan 8.
Polyunsaturated fatty acids (PUFAs) derived from marine sources, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are widely consumed as supplements within the community. However, the use of marine PUFAs in a therapeutic context is also increasing in patients receiving treatment for a range of cancer types. On balance, the literature suggests that marine PUFAs have potential as an effective adjuvant to chemotherapy treatment, may have direct anticancer effects, and may help ameliorate some of the secondary complications associated with cancer. Although a range of doses have been trialled, it would appear that supplementation of fish oil (>3 g per day) or EPA/DHA (>1 g EPA and >0.8 g DHA per day) is associated with positive clinical outcomes. However, further research is still required to determine the mechanisms via which marine PUFAs are mediating their effects. This review summarises our current understanding of marine PUFAs and cancer therapy.
多不饱和脂肪酸(PUFAs)来源于海洋,包括二十碳五烯酸(EPA)和二十二碳六烯酸(DHA),在社区中作为补充剂被广泛食用。然而,在接受各种癌症类型治疗的患者中,海洋 PUFAs 在治疗中的应用也在增加。总的来说,文献表明海洋 PUFAs 具有作为化疗治疗的有效辅助剂的潜力,可能具有直接的抗癌作用,并有助于改善与癌症相关的一些继发性并发症。尽管已经尝试了多种剂量,但似乎每天补充鱼油(>3 克)或 EPA/DHA(>1 克 EPA 和 >0.8 克 DHA 每天)与阳性临床结果相关。然而,仍然需要进一步的研究来确定海洋 PUFAs 发挥其作用的机制。这篇综述总结了我们目前对海洋 PUFAs 和癌症治疗的理解。